SHANGHAI, June 29, 2018 /PRNewswire/ — I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD 220 million, representing one of the largest amounts ever raised in Series C by an innovative biotech company in China. This round of funding was led by Hony Capital, with participations from Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, Singapore-based EDBI, and existing investors C-Bridge Capital and Tasly Capital. China Renaissance was designated as the sole financial advisor for this series of financing.
The proceeds of the financing will be used primarily to advance the pre-clinical and clinical development of a number of Best-in-Class and First-in-Class assets.
As a China-based innovative company specialized in oncology and autoimmune diseases, I-Mab Biopharma has rapidly built a globally competitive pipeline through its unique strength in target biology, antibody engineering as well as pre-clinical & clinical development. Currently, I-Mab has more than ten investigational drugs under development, and has forged partnerships with leading biotech and pharma companies, such as Genexine, Ferring Pharmaceuticals, MorphoSys AG, and CROs, which include WuXi Biologics, TigerMed and others.
A fresh round of fundraising came at the heels of the Company’s Series B financing of USD 150 million in March, 2017, and by retaining the world’s top investors in this round, I-Mab further demonstrated its development strengths and capabilities in innovative antibodies globally.
“We are very proud that our innovative research and clinical development capabilities are recognized by the leading investors. In a very short time, I-Mab has built a globally competitive pipeline and a highly experienced team to deliver the pipeline milestones. This round of financing will facilitate further development of our innovative assets in China and internationally”, said Dr. Jingwu Zang, the founder and CEO of I-Mab.
Facilitated by a merger between Third Venture Biotech and Tasgen Bio, which was followed by a Series B financing of USD 150 million in 2017, I-Mab has rapidly built a world-class R&D capability and highly experienced team.
I-Mab focuses on discovery and development of First-in-Class and Best-in-Class biologics in the areas of immuno-oncology and immuno-inflammation. The company has already submitted several IND applications and is prepared to submit additional INDs in order to initiate clinical trials in China and the US, including multiple Phase 2 and Phase 3 studies. I-Mab is on a fast track toward becoming an end-to-end fully integrated biopharma company.